By Martin Lock, Director, Process Development, Gene Therapy Program — University of Pennsylvania
Recombinant AAV is rapidly becoming the vector of choice for human gene therapy applications due to the ability to achieve prolonged gene expression in a variety of tissues without a significant immune response or toxicity. Our laboratory has discovered a number of novel AAV serotypes with enhanced gene expression and alternate tissue tropisms and has pioneered the study of these vectors for gene delivery.
Learn about Droplet Digital PCR (ddPCR™), how it works, and the technique's precision when determining AAV vector genome titers. ddPCR delivers a universal assay for all AAV vector types without some of the limitations of qPCR or the need to resort to separate methods.